RESUMO
PURPOSE: The survival after a pancreaticoduodenectomy, for a periampullary adenocarcinoma is limited. However, the improvement in perioperative management, and the development of interventional medicine have made the survival from that cancer favorable. Due to the anatomical proximity of periampullary tumors, surgeons perform same procedure. It is accepted that the outcome of periampullary cancers vary after resection. The purpose of this study was to evaluate the risk factors, and the differences in survival, from periampullary cancers according to the origin of the tumor. METHODS: From March 1992 to December 2000, 87 patients, with periampullary tumors, who underwent a pancreatico duodenectomy, were analyzed for the location of the tumor and the tumor status. Of the 87 patients, the 85 surviving more than 30 days were included in the statistic analysis. The survival was calculated using the Kaplan-Meier Method. The risk factors were also analyzed between the locations. RESULT: Of the 87 resected adenocarcinomas, 25 were pancreatic cancers, 30 distal CBD (common bile duct) cancers, 26 mpulla of Vater cancers and 6 duodenal cancers. The patients had a mean age of 60 (40~78) years. The total bilirubin, ALT, and CA 19-9 levels were statistically different for each cancer. There were no statistical differences between the cancer groups in operative methods, the amount of transfusion, postoperative hospital stay, and complications. The overall morbidity and mortality were 37 and 2%, respectively. The 5-year survival rates for the pancreatic, distal CBD, and Ampulla of Vater cancers were 9.6, 45.5, and 72.1%, respectively, was and were statistically significant (P<0.001). A univariate analysis of the 85 patients indicated that the predictors of long term survival included: a pathologic diagnosis of Ampulla of Vater cancer, absence of lymph node metastasis, tumor diameter<3 cm and complication. CONCLUSION: The factors influencing the survival were nodal metastasis, size of the tumor, age, and complications. The differences in the tumor biology will affect the survival, and although a pancreaticoduodenectomy remains the procedure of choice for periampullary tumors, adjuvant, or neoadjuvant, therapy for a pancreatic head tumor is especially needed.